NCT02450032

Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer

An Open, Multi-center Study to Determine the Antibody Response to 500µg G17DT Given at Weeks 0, 2, and 6 in the Treatment of Patients With Gastric Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Cancer Advances Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to investigate the antibody response generated by a 500µg dose of G17DT in patients with gastric cancer.

Detailed description

Another study, GC2, initiated prior to the start of this study investigated the appropriate dose and dosing schedule for G17DT in patients with Stage I-III gastric cancer. The highest dose tested in the GC2 study was 250µg. This dose was well tolerated but was not considered sufficiently immunogenic. Since tolerability had not constrained dosing up to 250µg, the GC5 study was designed to investigate a 500µg dose administered as a regimen of 0, 2, and 6 weeks.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
BIOLOGICAL	G17DT

Timeline

• Start date: 2000-02-01
• Primary completion: 2001-05-01
• Completion: 2001-05-01
• First posted: 2015-05-21
• Last updated: 2015-05-21

Locations

1 site across 1 country: United Kingdom